Akers Biosciences, Inc. (NASDAQ:AKER) has a beta value of 0.44 and has seen 929,888 shares traded in the last trading session. The company, currently valued at $16.57 Million, closed the last trade at $1.87 per share which meant it gained $0.05 on the day or 2.75% during that session. The AKER stock price is -373.26% off its 52-week high price of $8.85 and 17.11% above the 52-week low of $1.55. If we look at the company’s 10-day average daily trading volume, we find that it stood at 6.37 Million shares traded. The 3-month trading volume is 1.49 Million shares.
The consensus among analysts is that Akers Biosciences, Inc. (AKER) is a Buy stock at the moment, with a recommendation rating of 0. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 1 have rated it as a Hold, with 1 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is $0.
Akers Biosciences, Inc. (NASDAQ:AKER) trade information
Sporting 2.75% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Nov 16 when the AKER stock price touched $1.9989 or saw a rise of 6.45%. Year-to-date, Akers Biosciences, Inc. shares have moved -41.56%, while the 5-day performance has seen it change -6.97%. Over the past 30 days, the shares of Akers Biosciences, Inc. (NASDAQ:AKER) have changed -16.14%. Short interest in the company has seen 593.87 Million shares shorted with days to cover at 398.57.
Wall Street analysts have a consensus price target for the stock at $768, which means that the shares’ value could jump 40969.52% from current levels. The projected low price target is $768 while the price target rests at a high of $768. In that case, then, we find that the current price level is +40969.52% off the targeted high while a plunge would see the stock lose 40969.52% from current levels.
Akers Biosciences, Inc. (AKER) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +45.1% over the past 5 years. Earnings growth for 2020 is a modest +73.3%.
Akers Biosciences, Inc. (NASDAQ:AKER)’s Major holders
Insiders own 5.01% of the company shares, while shares held by institutions stand at 8.98% with a share float percentage of 9.45%. Investors are also buoyed by the number of investors in a company, with Akers Biosciences, Inc. having a total of 22 institutions that hold shares in the company. The top two institutional holders are Sabby Management, LLC with over 299.91 Thousand shares worth more than $674.8 Thousand. As of September 29, 2020, Sabby Management, LLC held 3.39% of shares outstanding.
The other major institutional holder is Susquehanna Fundamental Investments, LLC, with the holding of over 44.58 Thousand shares as of September 29, 2020. The firm’s total holdings are worth over $100.31 Thousand and represent 0.5% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Extended Market Index Fund and DFA Tax-Managed U.S. Small Cap Portfolio. As of June 29, 2020, the former fund manager holds about 0.07% shares in the company for having 5991 shares of worth $20.85 Thousand while later fund manager owns 4Thousand shares of worth $20.76 Thousand as of July 30, 2020, which makes it owner of about 0.05% of company’s outstanding stock.